SCHEMBL22736788

SCHEMBL22736788

Cc1ccc(-c2nc3ccccc3c(=O)n2C2CCC2)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.52
KDM4E B2RXH2 3/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
ATM Q13315 1/20 0.50
MAPK1 P28482 1/20 0.50
TDO2 P48775 2/20 0.48
IDO2 Q6ZQW0 2/20 0.48
ALDH1A1 P00352 4/20 0.46
IDO1 P14902 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 3/20 0.43
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
APAF1 O14727 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22720124 0.98 GAA (0.59) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720182 0.97 GAA (0.61) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720121 0.97 GAA (0.61) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720194 0.95 GAA (0.52) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22736814 0.92 GAA (0.47) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720108 0.91 KDM4E (0.48) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22736789 0.91 KDM4E (0.48) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720084 0.91 GAA (0.43) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720118 0.90 MAPK1 (0.47) GAAALOX15TSHRKDM4EKMT2A
SCHEMBL22720176 0.88 ALOX15 (0.46) GAAALOX15TSHRKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020239050-A1 2-(2-CHLORO-4-METHYLPHENYL)QUINAZOLINE-4(3H)-KETONE COMPOUND AND MEDICAL USE THEREOF 中国人民解放军军事科学院军事医学研究院 2020-12-03 WO disclosed